Phase I study evaluating safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-428, first-in-class mesothelin (MSLN)-CD40 bispecific, in patients (pts) with advanced solid tumours

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Luke, JJ; Fong, L; Chung, K; Tolcher, AW; Kelly, K; Hollebecque, A; Le Tourneau, C; Subbiah, V; Tsai, F; Kao, S; Cassier, P; Khasraw, M; Allaire, K; Fan, F; Fang, H; Patel, M; Henner, W; Hayflick, J; McDevitt, M; Barlesi, F

Published Date

  • October 1, 2019

Published In

Volume / Issue

  • 30 /

Published By


  • 2

Electronic International Standard Serial Number (EISSN)

  • 1569-8041

International Standard Serial Number (ISSN)

  • 0923-7534

Conference Name

  • 44th Congress of the European-Society-for-Medical-Oncology (ESMO)

Conference Location

  • Barcelona, SPAIN

Conference Start Date

  • September 27, 2019

Conference End Date

  • October 1, 2019